Norbrook
Loxicom 1 mg for dogs 100 chewable tablets

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs

Some countries require a prescription to be issued for the sale of this drug.

Loxicom 1 mg chewable tablets for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION OF Loxicom

Each chewable tablet contains:

Active substance:

Meloxicam 1 mg

For a full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM OF Loxicom

Chewable tablet.
Light brown oval biconvex tablet with a score line on one face and plain on the other. The tablets can be broken into equal halves.

4.CLINICAL PARTICULARS OF Loxicom

4.1. Target species

Dogs

4.2. Indications for use, specifying the target species

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

4.3. Contraindications

Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic disorders
Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.

4.4. Special warnings for each target species

None

4.5. Special precautions for use

Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
This veterinary medicinal product for dogs should not be used in cats as it is not suitable for use in this species. In cats, a meloxicam containing oral suspension authorised for that species should be used.
Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases, haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3).

4.8 Interaction with other medicinal products and other forms of interaction

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. This veterinary medicinal product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the veterinary medicinal products used previously.

4.9 Amounts to be administered and administration route

Oral use.

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight. Alternatively, therapy may be initiated with a solution for injection containing 5 mg meloxicam/ml.

Each chewable tablet contains 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog, respectively.
Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal. The tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.

Dose scheme for the maintenance dose:

Body weight (kg): Number of chewable tablets 1 mg; mg/kg 
4.0-7.0:  ½;   0.13-0.1 
7.1-10.0:  1;   0.14-0.1 
10.1-15.0:  1½;    0.15-0.1 
15.1-20.0:  2;    0.13-0.1 

Body weight (kg): Number of chewable tablets 2.5 mg; mg/kg
20.1-25.0:  1;  0.12-0.1 
25.1-35.0:  1½;  0.15-0.1 
35.1-50.0:  2;  0.14-0.1 

The use of a meloxicam containing oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of meloxicam containing oral suspension for dogs is recommended.
A clinical response is normally seen within 3-4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.
To ensure correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing or overdosing.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In case of overdose, symptomatic treatment should be initiated.

4.11 Withdrawal period

Not applicable.

5. PHARMACOLOGICAL PROPERTIES OF Loxicom

Pharmacotherapeutic group:

Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids (oxicams), ATC vet code: QM01AC06

5.1. Pharmacodynamic properties

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

5.2. Pharmacokinetic properties

Absorption

Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the veterinary medicinal product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.

Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

Elimination

Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.


6. PHARMACEUTICAL PARTICULARS OF Loxicom

6.1 List of excipients

Sodium starch glycolate, type A
Spray dried pork liver
Lactose monohydrate
Povidone K30
Sucrose
Microcrystalline cellulose and guar gum
Microcrystalline cellulose
Wheatgerm defatted flour
Yeast extract (dried)
Magnesium stearate

6.2. Incompatibilities

Not applicable.

6.3. Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 18 months.
Any unused half tablets may be returned to open blister and stored for up to 24 hours.

6.4. Special precautions for storage

Do not store above 25°C.
Store in the original package in order to protect from light.

61.50
Order within 13h 10m 16s (before 12AM)
And receive your order
on Wednesday 7 December
AIR FREIGHT

Customers who buy this product, usually buy: